A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
NCT05543629 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2025-03-18
Summary
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Conditions
Interventions
- BIOLOGICAL
-
BMS-986442
Specified dose on specified days
- BIOLOGICAL
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Pemexetred
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-04
- Primary Completion
- 2024-09-12
- Completion
- 2024-09-12
- FDA Drug
- Yes
Countries
- United States
- Australia
- Italy
- Poland
- Spain
Study Locations
More Related Trials
-
BMS-986012 in Relapsed/Refractory SCLC
NCT02247349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
NCT03353675 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of BMS-986012 in Combination With Platinum and Etoposide
NCT02815592 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276 ·Status: RECRUITING ·Phase: PHASE3
-
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
NCT05469178 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
NCT04702880 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
NCT05005273 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
NCT04151563 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
NCT01024062 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
NCT00461110 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133 ·Status: TERMINATED ·Phase: PHASE2
-
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
NCT04325698 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
NCT00006229 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
NCT05500092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
NCT02409368 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04466917 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745 ·Status: RECRUITING ·Phase: PHASE2/PHASE3